Prof Patrick Arbuthnot

Patrick Arbuthnot is a South African molecular biologist and professor at the University of the Witwatersrand, widely recognized for his work in gene therapy and nucleic acid–based therapeutics. His research centers on developing innovative treatments for chronic hepatitis B, with particular emphasis on RNA interference, designer nucleases, and viral vector–mediated gene editing. He has played a prominent role in advancing translational strategies aimed at achieving a functional cure for persistent viral infections.

Recent publications highlight sustained suppression of hepatitis B virus gene expression using engineered adeno-associated viral vectors and artificial primary microRNAs. His work explores both DNA- and RNA-based delivery systems, addressing challenges such as vector immunotoxicity, intracellular RNA processing, and safe targeting of viral cccDNA. Reviews and experimental studies demonstrate strong expertise in AAV biology, in vitro–transcribed RNA technologies, and genome editing platforms.

Beyond antiviral therapeutics, his scholarship engages vaccine innovation, lipid nanoparticle delivery of self-amplifying RNA, and strategies to strengthen vaccine manufacturing capacity in Africa. By bridging gene therapy and next-generation vaccine technologies, he contributes to global discussions on equitable access, regulatory advancement, and sustainable biotechnology development, positioning his research at the intersection of molecular medicine and public health.